

PG-110: A Bi-Specific ActRII/Myostatin Blocker for Metabolic and Musculoskeletal Health



METABOLIC	Lead																														
Product Type	Antibody																														
Indication	Sarcopenic Obesity & Metabolic Dysfunction																														
Target	Activin type 2 receptors (ActRII) and Myostatin																														
MoA(Mechanism of Action)	<p>A novel bispecific antibody for selective fat loss, muscle preservation, and bone health</p>																														
Competitiveness	<table border="1"> <thead> <tr> <th>Molecule</th> <th>Vehicle</th> <th>Semaglutide</th> <th>Semaglutide & Bimagrumb</th> <th>Semaglutide & Trevogrumab</th> <th>Semaglutide & PG-110</th> </tr> </thead> <tbody> <tr> <td>Structure</td> <td>Buffer</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Fat Mass Loss</td> <td>10 %</td> <td>45.6 %</td> <td>55.5 %</td> <td>48.9 %</td> <td>58.6 %</td> </tr> <tr> <td>Lean Mass Loss</td> <td>6.2 %</td> <td>12.5 %</td> <td>3.3 %</td> <td>9.9 %</td> <td>1.5 %</td> </tr> <tr> <td>Bone Mineral Density Change</td> <td>15.9 %</td> <td>10.4 %</td> <td>16.1 %</td> <td>15.5 %</td> <td>22.3 %</td> </tr> </tbody> </table>	Molecule	Vehicle	Semaglutide	Semaglutide & Bimagrumb	Semaglutide & Trevogrumab	Semaglutide & PG-110	Structure	Buffer					Fat Mass Loss	10 %	45.6 %	55.5 %	48.9 %	58.6 %	Lean Mass Loss	6.2 %	12.5 %	3.3 %	9.9 %	1.5 %	Bone Mineral Density Change	15.9 %	10.4 %	16.1 %	15.5 %	22.3 %
Molecule	Vehicle	Semaglutide	Semaglutide & Bimagrumb	Semaglutide & Trevogrumab	Semaglutide & PG-110																										
Structure	Buffer																														
Fat Mass Loss	10 %	45.6 %	55.5 %	48.9 %	58.6 %																										
Lean Mass Loss	6.2 %	12.5 %	3.3 %	9.9 %	1.5 %																										
Bone Mineral Density Change	15.9 %	10.4 %	16.1 %	15.5 %	22.3 %																										
Development Stage	Lead																														
Route of Administration	SC Monthly Dosing – Patient-friendly alternative to IV-based muscle therapies																														

Any unauthorized distribution or reproduction of this material is strictly prohibited.